AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Quality of life: an important element of treatment value

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1669963> since 2018-06-24T18:47:03Z

Published version:

DOI:10.1016/S1470-2045(17)30697-6

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Quality of life results: a fine dowel in the mosaic of treatment value.

Massimo Di Maio, MD

Division of Medical Oncology, “Ordine Mauriziano” Hospital, Turin, Italy

Department of Oncology, University of Turin, Turin, Italy

Corresponding author:

Prof. Massimo Di Maio

Department of Oncology, University of Turin; Division of Medical Oncology, Ordine Mauriziano Hospital, Via Magellano 1, Turin 10128, Italy.

Phone: +39 011 5082032

Fax: +39 011 9015184

E-mail: massimo.dimaio@unito.it

In the era of platinum-based chemotherapy, the attempt of improving quality of life (QoL) of patients with advanced non-small cell lung cancer (NSCLC) using a less toxic treatment was often disappointing. In a randomized trial comparing cisplatin-based treatment to a “platinum-free” combination, although the latter was associated with a significantly reduced amount of toxicity and an improvement in some specific QoL items, the primary endpoint of improving global QoL was not met [1]. The lesson was that, in patients suffering from a disease often associated with relevant symptoms, reduction of treatment-related toxicity in itself is not enough to improve global QoL, and a better control of disease is needed to shift the QoL balance.

In recent years, randomized trials comparing tyrosine kinase inhibitors with platinum-based chemotherapy in patients with oncogene-addicted advanced NSCLC have repeatedly demonstrated that, in a properly selected population, different efficacy of treatments can produce a relevant difference in patients’ QoL [2-4]. Now, a similar benefit has been shown within a randomized trial comparing the immune checkpoint inhibitor pembrolizumab with platinum-based chemotherapy as first-line treatment of patients with advanced NSCLC, selected for the expression of programmed death ligand 1 (PD-L1) on at least 50% of tumor cells [5]. Primary results of the trial were published in 2016: pembrolizumab was associated with a significant prolongation in progression-free survival (primary endpoint) and overall survival, and with fewer adverse events [6]. Evaluation of patient-reported outcomes was an exploratory endpoint, and it was not included at all among the results presented in the primary publication. In the article by Brahmer *et al.* now published in The Lancet Oncology, pembrolizumab was significantly better than platinum-based chemotherapy in terms of both improvement in global QoL scores and time to deterioration of tumor symptoms (cough, dyspnea, chest pain) [5]. From a methodological point of view, proper analysis, presentations

and interpretation of clinical relevance of QoL data is not easy, particularly in settings like advanced NSCLC, where the number of missing questionnaires is not negligible, and most missing data are not at random, being related to disease progression and worsening of patient's conditions [7].

Given the already known benefit in efficacy and in toxicity, the significant difference in global QoL favoring pembrolizumab over platinum-based chemotherapy is not surprising. Primary publication of the trial (including progression-free survival, overall survival, objective response rate and toxicity data) was already sufficient to convince scientific community about the relevance of the clinical results obtained with pembrolizumab in these patients. However, even when the experimental treatment demonstrates a clinically relevant improvement in survival endpoints, patient-reported outcomes and QoL results are still of interest, allowing a more complete definition of benefits and harms associated with treatment [8]. It is not surprising that both the framework proposed by the American Society of Clinical Oncology (ASCO) [9] and the European Society of Medical Oncology (ESMO) magnitude of benefit scale [10] evaluating the value of anticancer treatments include QoL results among the parameters considered for the evaluation of study results. Namely, in the ASCO framework, a “palliation bonus” (10 points) is awarded by the experimental treatment, if a statistically significant improvement in cancer-related symptoms is shown, and a “QoL bonus” (10 points) is awarded if a statistically significant improvement in QoL is demonstrated [9]. Similarly, in the ESMO scale, preliminary scores based on treatment efficacy can be upgraded when the experimental arm demonstrates improved QoL or delayed deterioration in QoL (or substantial reduction in severe toxicity) [10].

Based on these tools, a complete evaluation of treatment value can be properly made only if scientific community could evaluate QoL results at the same time of the other

trial endpoints [8]. The ancillary paper dedicated to QoL results obtained with first-line pembrolizumab is being published almost 1 year later than the primary publication. Admittedly, this delay is common for many trials, although it would be desirable that QoL results were available along with the primary publication, to allow a timely evaluation of the benefit / risk ratio and of the value of the treatment.

The recent update of ASCO clinical practice guidelines [11] includes a strong recommendation that, in the absence of contraindications to immune checkpoint therapy, single-agent pembrolizumab should be offered as standard treatment to patients with both non-squamous and squamous NSCLC, characterized by high PD-L1 expression. The results by Brahmer *et al.*, showing a clear benefit in QoL, reinforce the evidence supporting pembrolizumab as first-line treatment of patients with advanced NSCLC selected for the expression of PD-L1 on at least 50% of tumor cells.

Conflicts of interest statement

Massimo Di Maio acted as consultant for AstraZeneca, Bayer, Janssen, Bristol Myers Squibb, and Eli Lilly, and received speaker's fee from Merck Sharp & Dohme.

References

1. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 2003 Aug 15;21(16):3025-34.
2. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.
3. Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH Investigators. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. *J Thorac Oncol*. 2012 Dec;7(12):1830-44.
4. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013 Sep 20;31(27):3342-50.

5. Julie R Brahmer, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Jin Zhang, Gregory M Lubiniecki, Anne C Deitz, Reshma Rangwala, Martin Reck. Randomised phase 3 trial of pembrolizumab 1 vs chemotherapy in advanced NSCLC with PD-L1 TPS $\geq 50\%$ (KEYNOTE-024): health-related quality of life. *Lancet Oncology in press*
6. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2016 Nov 10;375(19):1823-1833.
7. Fiteni F, Anota A, Westeel V, Bonnetain F. Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review. *BMC Cancer*. 2016 Feb 18;16:122.
8. Di Maio M, Perrone F. Lessons from clinical trials on quality-of-life assessment in ovarian cancer trials. *Ann Oncol*. 2016 Jun;27(6):961-2.
9. Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. *J Clin Oncol*. 2016 Aug 20;34(24):2925-34.
10. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). *Ann Oncol*. 2015 Aug;26(8):1547-73.
11. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J*

Clin Oncol. 2017 Aug 14;JCO2017746065. doi: 10.1200/JCO.2017.74.6065. [Epub ahead of print]